Lekakis John, Tsiodras Sotirios, Ikonomidis Ignatios, Palios John, Poulakou Garyfalia, Rallidis Loukianos, Antoniadou Anastasia, Panagopoulos Periklis, Papadopoulos Antonios, Giamarellou Helen, Kremastinos Dimitrios T
2nd Department of Cardiology, Attikon University Hospital, University of Athens Medical School, Athens, Greece.
Clin Sci (Lond). 2008 Sep;115(6):189-96. doi: 10.1042/CS20070353.
A metabolic syndrome associated with atherosclerosis and cardiovascular disease has been described in HIV-positive individuals. In the present study we investigated whether HIV-positive individuals and CAD (coronary artery disease) patients have similarities in their vascular function and structure. In a case-control study, we compared measurements of carotid artery IMT (intima-media thickness) and brachial artery FMD (flow-mediated vasodilation) in HIV-positive individuals with age- and sex-matched controls with similar risk factors and patients with established CAD. Seventy-one HIV patients, age 42+/-13.9 years (91% male), were compared with 29 CAD patients and 25 controls. HIV patients had higher IMT than controls and similar IMT to CAD patients (0.64+/-0.2 compared with 0.55+/-0.05 and 0.66+/-0.08 mm respectively; F=4.2, P=0.01). Patients taking protease inhibitors had higher IMT (0.69+/-0.2 compared with 0.57+/-0.15 mm; P=0.01), blood pressure, cholesterol and triacylglycerols than those not taking protease inhibtors (P<0.05). In multiple regression analyses, increasing blood pressure (beta: 0.37, P=0.001), glucose (beta: 0.26, P=0.016), cholesterol (beta: 0.24, P=0.033), duration of HIV disease (beta: 0.33, P=0.008) and use of protease inhibitors (beta: 0.27, P=0.04) were the most important determinants of IMT respectively. FMD was associated only with triacylglycerol measurements. Patients with HIV present arterial changes resembling those found in patients with atherosclerotic cardiovascular disease. These vascular changes are closely related to protease-inhibitor-induced changes of metabolic parameters. Thus intensive treatment of these metabolic parameters might retard atherosclerosis in HIV patients.
在HIV阳性个体中已发现一种与动脉粥样硬化和心血管疾病相关的代谢综合征。在本研究中,我们调查了HIV阳性个体与冠心病(CAD)患者在血管功能和结构上是否存在相似之处。在一项病例对照研究中,我们比较了HIV阳性个体、具有相似危险因素的年龄和性别匹配的对照组以及确诊CAD患者的颈动脉内膜中层厚度(IMT)和肱动脉血流介导的血管舒张功能(FMD)测量值。71名年龄为42±13.9岁(91%为男性)的HIV患者与29名CAD患者和25名对照组进行了比较。HIV患者的IMT高于对照组,与CAD患者相似(分别为0.64±0.2与0.55±0.05和0.66±0.08mm;F = 4.2,P = 0.01)。服用蛋白酶抑制剂的患者比未服用蛋白酶抑制剂的患者有更高的IMT(0.69±0.2与0.57±0.15mm;P = 0.01)、血压、胆固醇和三酰甘油(P < 0.05)。在多元回归分析中,血压升高(β:0.37,P = 0.001)、血糖(β:0.26,P = 0.016)、胆固醇(β:0.24,P = 0.033)、HIV疾病持续时间(β:0.33,P = 0.008)和蛋白酶抑制剂的使用(β:0.27,P = 0.04)分别是IMT最重要的决定因素。FMD仅与三酰甘油测量值相关。HIV患者出现的动脉变化类似于动脉粥样硬化性心血管疾病患者的变化。这些血管变化与蛋白酶抑制剂引起的代谢参数变化密切相关。因此,对这些代谢参数进行强化治疗可能会延缓HIV患者的动脉粥样硬化进程。